Nirvana Therapeutics

Nirvana Therapeutics is a biotechnology company focused on developing next-generation oral antiviral therapies for SARS-CoV-2 and other respiratory viruses. The company was founded by leading scientists from Columbia University to address the ongoing need for effective, mutation-resistant treatments for COVID-19. Their primary approach involves targeting the 3C-like protease (3CLpro), an essential enzyme for viral replication that is highly conserved across variants. Nirvana's lead candidate, NIRV-201, is a small molecule inhibitor designed to be administered orally without the need for a pharmacokinetic booster. This profile aims to reduce drug-drug interactions and improve patient compliance compared to existing therapies. The company is backed by prominent venture capital firms and continues to advance its pipeline toward clinical evaluation.